List of Excipients in Branded Drug ROZLYTREK

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	ROZLYTREK	entrectinib	50242-091	ANHYDROUS LACTOSE	2038-07-18
Genentech Inc	ROZLYTREK	entrectinib	50242-091	CELLULOSE, MICROCRYSTALLINE	2038-07-18
Genentech Inc	ROZLYTREK	entrectinib	50242-091	CROSPOVIDONE	2038-07-18
Genentech Inc	ROZLYTREK	entrectinib	50242-091	FERRIC OXIDE YELLOW	2038-07-18
Genentech Inc	ROZLYTREK	entrectinib	50242-091	HYPROMELLOSE	2038-07-18

Rozlytrek Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Rozlytrek (entrectinib) is a small-molecule, tumor-agnostic kinase inhibitor marketed by Genentech, a member of the Roche Group. Its formulation opportunity is concentrated in pediatric delivery, swallowability, taste management, excipient substitution, and supply-chain efficiency rather than in biosimilar development. The marketed product uses conventional capsule excipients and a multiparticulate oral-pellet presentation that creates a more defensible formulation platform for pediatric use.[1,2]

What is Rozlytrek and how is it regulated?

Rozlytrek contains entrectinib, a potent inhibitor of TRK proteins encoded by NTRK1, NTRK2, and NTRK3, as well as ROS1. The U.S. Food and Drug Administration approved it in August 2019 for:

• Adults and pediatric patients with solid tumors harboring an NTRK gene fusion when metastatic or surgically resection would cause severe morbidity and no satisfactory alternative exists.
• Adults with ROS1-positive metastatic non-small cell lung cancer.[1]

The product is a small molecule, not a biologic. Biosimilar competition under the Public Health Service Act therefore does not apply. Future competition would arise through abbreviated new drug applications, 505(b)(2) applications, authorized generics, or differentiated formulations.

FDA dosage forms and strengths

Product	Strengths	Administration	Commercial relevance
Capsules	100 mg, 200 mg	Swallowed whole	Primary adult presentation
Oral pellets	50 mg per sachet or dose unit, depending on market presentation	Administered orally; intended for patients unable to swallow capsules	Pediatric and dysphagia-focused presentation

The oral-pellet presentation is commercially important because NTRK-fusion cancers can occur in children, while conventional capsules impose a practical barrier for infants and younger pediatric patients. The dosage form also creates opportunities for generic developers to compete through multiparticulate technology, taste masking, dose flexibility, and administration compatibility.

What excipients are used in Rozlytrek capsules?

The U.S. prescribing information identifies the core capsule formulation as containing lactose monohydrate, hypromellose, crospovidone, magnesium stearate, and colloidal silicon dioxide. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide, and colorants that vary by strength.[1]

Capsule excipient functions

Excipient	Primary function	Formulation implication
Lactose monohydrate	Diluent and bulking agent	Low-cost, established oral solid-dose excipient; may limit positioning for lactose-sensitive patients
Hypromellose	Binder or matrix-forming aid	Supports granulation and mechanical integrity
Crospovidone	Superdisintegrant	Promotes rapid capsule-fill disintegration
Magnesium stearate	Lubricant	Controls powder flow and prevents adhesion during encapsulation
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder handling and content uniformity
Gelatin	Capsule shell	Conventional hard-gelatin delivery system
Titanium dioxide and iron oxides	Opacifiers and colorants	Support product identification and light protection

The capsule composition is conventional. Its commercial value lies in manufacturability, dose strength, and established regulatory history rather than in a novel excipient system.

What formulation risks arise from the capsule excipient system?

The capsule formulation creates four potential development issues:

1. Lactose sensitivity claims may restrict use in selected patient groups, although the amount in a finished dose is generally small.
2. Gelatin excludes patients seeking vegetarian or non-animal-derived capsule shells.
3. Colorant selection may create regional regulatory or labeling differences.
4. The capsule format is unsuitable for many young pediatric patients and patients with severe dysphagia.

These issues create a substitution opportunity for hard hypromellose capsules, liquid-filled systems, granules, or oral multiparticulates.

What excipients are used in Rozlytrek oral pellets?

The oral-pellet presentation uses a multiparticulate platform based on excipients including mannitol, microcrystalline cellulose, hypromellose, crospovidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate, according to product labeling and regulatory product information.[2,3]

The precise excipient profile can differ by jurisdiction and presentation. The commercial objective is to produce small, dose-flexible particles that can be administered without swallowing a conventional capsule.

Oral-pellet excipient functions

Excipient	Likely function in the pellet system	Commercial purpose
Mannitol	Diluent and palatability-supporting filler	Provides a pediatric-compatible solid base and can improve mouthfeel
Microcrystalline cellulose	Pelletization aid and structural filler	Supports extrusion, spheronization, or other multiparticulate processing
Hypromellose	Binder or release-controlling polymer	Supports pellet integrity and drug-release control
Crospovidone	Disintegrant	Promotes rapid breakup after administration
Sodium lauryl sulfate	Wetting or solubilization aid	Helps manage wetting of a poorly soluble active ingredient
Colloidal silicon dioxide	Glidant	Improves powder flow and process consistency
Magnesium stearate	Lubricant	Reduces manufacturing friction and sticking

The presence of a wetting agent in the pellet platform is strategically relevant. Entrectinib is a low-dose, high-potency compound, but its oral performance still depends on dissolution and absorption. Multiparticulate processing can improve dispersion and dose uniformity while permitting pediatric administration.

What excipient strategy best supports a competing Rozlytrek product?

A competitive strategy should separate the adult generic opportunity from the pediatric formulation opportunity.

Adult capsule strategy

For an ANDA targeting the 100 mg and 200 mg capsules, the lowest-risk approach is a conventional immediate-release powder blend using:

• A lactose or lactose-free diluent.
• Crospovidone or croscarmellose sodium as the disintegrant.
• Colloidal silicon dioxide as the glidant.
• Magnesium stearate or an alternative lubricant.
• Gelatin or hypromellose capsule shells.

The principal development requirements are dissolution matching, assay and content uniformity, impurity control, capsule-fill reproducibility, and bioequivalence. A generic company does not necessarily need to duplicate every inactive ingredient. It must demonstrate that the formulation meets applicable quality and bioequivalence requirements and does not introduce clinically relevant differences.

Pediatric multiparticulate strategy

A more valuable formulation opportunity is a 50 mg-equivalent pediatric product using:

• Taste-masked drug-loaded pellets.
• Sprinkle-compatible granules.
• Sachets with flexible dose instructions.
• A low-volume oral suspension made from reconstitutable powder.
• A coating system that limits immediate bitterness without delaying release.

Potential taste-masking technologies include polymer coating, ion-exchange resins, lipid barriers, cyclodextrin complexes, and multiparticulate encapsulation. The preferred technology must preserve rapid release and avoid excessive variability when administered with food, soft food, or liquids.

A developer should prioritize dose flexibility. Pediatric entrectinib dosing is weight-based, so a product that permits accurate delivery across weight bands may have greater commercial value than a simple capsule copy.

What formulations are protected by Rozlytrek-related intellectual property?

Rozlytrek's intellectual-property position can be divided into four layers:

1. The entrectinib compound.
2. Salt, polymorph, crystal, and solid-state forms.
3. Pharmaceutical compositions and dosage forms.
4. Therapeutic use claims, including use in NTRK-fusion and ROS1-positive cancers.

Excipient selection alone is usually a weak patent barrier. A stronger formulation patent would need to claim a defined combination of entrectinib, excipients, particle attributes, dissolution performance, stability profile, or administration method.

Formulation patents with practical commercial value

The most commercially meaningful claim types would cover:

• A defined particle-size distribution.
• Drug-loaded pellets with a specific polymer coating.
• A taste-masked multiparticulate dosage form.
• A dosage form that maintains bioavailability across fed and fasted conditions.
• A stable oral liquid or reconstitutable suspension.
• A pediatric administration method using a specific food vehicle.
• A formulation that reduces food-effect variability.
• A defined impurity profile or manufacturing process.

A generic manufacturer may avoid literal infringement by changing the binder, disintegrant, lubricant, coating polymer, or manufacturing process. A patent estate is stronger when its claims are tied to measurable product attributes rather than a narrow ingredient list.

What is the Orange Book status of Rozlytrek?

Rozlytrek is an FDA-approved small molecule and is eligible for Orange Book listing. The relevant protection layers can include active-ingredient patents, method-of-use patents, and formulation or composition patents.[4]

The Orange Book should be reviewed for the current patent numbers, expiration dates, pediatric exclusivity adjustments, and any litigation certifications. The critical distinction is between:

• Patents listed for the approved product.
• Patents covering broader entrectinib uses.
• Patents not eligible for Orange Book listing.
• Regulatory exclusivity that expires separately from patent protection.

The product's regulatory exclusivity began with its 2019 approval. The exact commercial entry date for an ANDA depends on patent certifications, litigation, settlement terms, pediatric exclusivity, and any applicable non-patent exclusivity.

When does Rozlytrek lose exclusivity?

The product's key regulatory dates are:

Event	Date or status
FDA approval	August 15, 2019
New chemical entity exclusivity	Generally four years from approval for ANDA submission purposes and five years for approval, subject to statutory exceptions
Orphan-drug designations	May provide seven years of orphan exclusivity for qualifying indications
Pediatric exclusivity	Adds six months if awarded after completion of an FDA-requested pediatric program
Patent expiry	Depends on the specific Orange Book-listed patent family and patent-term adjustments
Generic entry	Controlled by patent certifications, litigation, settlement, and exclusivity barriers

Entrectinib's tumor-agnostic indication may create overlapping exclusivity questions because the same active ingredient is approved for multiple molecularly defined uses. Orphan-drug exclusivity is indication-specific, while composition patents can block broader commercial substitution.

A company assessing entry should model at least three scenarios:

1. Entry after the earliest unblocked Orange Book patent.
2. Entry after litigation resolution or settlement.
3. At-risk launch before final patent resolution, subject to injunction and damages exposure.

Which companies are challenging Rozlytrek?

Publicly available FDA materials do not establish a single dominant generic challenger comparable to the large first-wave challengers seen for high-volume primary-care drugs. Rozlytrek's limited patient population, complex tumor-genomic positioning, and relatively specialized pediatric dosage form reduce the incentive for early multi-company ANDA filings.

The likely competitive field includes:

• Large generic manufacturers with oncology portfolios.
• Specialty generic companies with pediatric multiparticulate capabilities.
• Contract development and manufacturing organizations with pelletization capacity.
• Regional manufacturers seeking rights outside the United States.
• Specialty pharmaceutical companies pursuing 505(b)(2) formulations.

The first commercially credible challenger may not be the lowest-cost capsule manufacturer. It may be the company that obtains a reliable pediatric product with flexible dosing and acceptable taste.

What Paragraph IV challenges and settlement risks apply?

A Paragraph IV certification could target an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. If the patent holder files suit within the statutory period, the FDA approval of the ANDA can be stayed for up to 30 months, subject to statutory exceptions and court developments.[5]

For Rozlytrek, the commercial value of a Paragraph IV challenge depends on:

• Whether composition patents remain active.
• Whether the challenger can design around formulation claims.
• Whether method-of-use patents cover the commercial labels.
• Whether pediatric and adult indications can be carved out separately.
• Whether a first-filer obtains 180-day exclusivity.
• Whether a settlement permits a date-certain launch.

Settlement agreements can produce an entry date earlier than patent expiry but later than the initial challenge. The Federal Trade Commission reviews brand-generic settlement terms for potential anticompetitive provisions under applicable law.[6]

How strong is the Rozlytrek formulation estate?

The formulation estate is strategically meaningful but likely less impenetrable than the compound estate.

Estate component	Relative barrier	Commercial assessment
Entrectinib compound	High	Usually the principal barrier to early generic entry
Approved capsule composition	Moderate	Conventional excipients permit design-around options
Oral pellets	Moderate to high	Pediatric manufacturing, taste, and dose uniformity raise technical barriers
Method of treatment	Variable	Strength depends on claim scope and label carve-out options
Manufacturing process	Moderate	Can raise process-development costs but may be avoidable
Excipient combination alone	Low to moderate	Usually vulnerable to substitution unless linked to performance data

The oral-pellet product has greater practical differentiation than the capsule. A competing company must reproduce not only chemical equivalence but also pellet size, dose uniformity, dispersibility, administration performance, and pediatric acceptability.

What commercial opportunities exist for excipient suppliers and formulation companies?

Pediatric excipients and taste masking

The clearest opportunity is a taste-masked multiparticulate platform. Suppliers can position:

• Neutral-tasting mannitol systems.
• Low-moisture pelletization excipients.
• Functional coating polymers.
• Modified-release or barrier coatings.
• High-purity wetting agents.
• Direct-compression and extrusion-spheronization grades.

A successful platform should support rapid dissolution, low drug loading variability, and administration with soft food.

Lactose-free and gelatin-free alternatives

A lactose-free capsule may address patient and institutional procurement preferences. A hypromellose capsule could provide a non-animal-derived alternative, although the commercial benefit depends on labeling, cost, and whether the new formulation requires a separate regulatory pathway.

Oral suspension and reconstitution systems

A stable liquid or reconstitutable suspension could target infants and patients with severe swallowing limitations. The technical barriers include:

• Chemical stability of entrectinib in aqueous media.
• Sedimentation and redispersibility.
• Microbial control.
• Dose uniformity after storage.
• Food and beverage compatibility.
• Packaging protection from light and moisture.

This route is more likely to require a 505(b)(2) application than a straightforward ANDA if the formulation materially changes dosage form, administration, or pharmacokinetics.

Regional licensing

The most attractive licensing structures may involve:

• Rights to pediatric formulations outside the United States.
• Co-development of a sprinkle product.
• Regional commercialization of oral pellets.
• Technology licensing for taste masking.
• Supply agreements for specialized excipients or coated pellets.

Because entrectinib is used in molecularly selected cancers, a partner with oncology diagnostics, pediatric hospital access, and specialty-distribution capabilities may be more valuable than a high-volume primary-care distributor.

How does Rozlytrek compare with competing NTRK therapies?

Product	Active ingredient	Main formulation opportunity	Competitive issue
Rozlytrek	Entrectinib	Capsules and oral pellets	Pediatric delivery and CNS-active tumor-agnostic use
Vitrakvi	Larotrectinib	Oral solution and capsules	Strong liquid-pediatric positioning
Repotrectinib	Repotrectinib	Adult oral solid dose	ROS1 competition; less direct pediatric formulation overlap
Larotrectinib generics	Larotrectinib	Liquid and capsule substitution	May reach pediatric patients through established liquid experience

Vitrakvi's oral solution creates a direct benchmark for pediatric liquid delivery. Rozlytrek's pellet platform can compete through stability, portability, dose precision, and reduced microbial risk compared with an aqueous product. A liquid competitor, however, may have a simpler administration profile for infants.

What generic launch risks exist for Rozlytrek?

The main launch risks are:

• Patent litigation under Paragraph IV.
• Limited market size relative to development cost.
• Difficulty demonstrating bioequivalence for multiparticulate products.
• Food-effect differences.
• Pediatric taste failure.
• Inability to reproduce pellet size and dose uniformity.
• Limited access to NTRK and ROS1 diagnostic testing.
• Small patient pools and fragmented oncology prescribing.
• Potential need for separate development of pediatric and adult products.

The revenue opportunity is concentrated rather than broad. A challenger needs a high gross margin, efficient specialty distribution, and a formulation that avoids costly clinical bridging studies.

Key Takeaways

• Rozlytrek is an entrectinib small-molecule product marketed in capsules and an oral-pellet presentation.
• The capsule uses conventional excipients and is comparatively straightforward to design around.
• The oral-pellet platform is the more defensible commercial asset because it addresses pediatric dosing and swallowing limitations.
• Excipient suppliers have opportunities in taste masking, pelletization, lactose-free systems, hypromellose capsules, and reconstitutable suspensions.
• Biosimilar competition does not apply; future competition will come through ANDA and 505(b)(2) pathways.
• The primary legal risks are Orange Book-listed patents, Paragraph IV litigation, method-of-use claims, and settlement-controlled entry dates.
• A successful entrant needs more than chemical equivalence. It must demonstrate reliable pediatric administration, dose flexibility, dissolution, and manufacturing consistency.
• Vitrakvi provides the strongest pediatric formulation comparator because it includes an oral solution.

FAQs

Can Rozlytrek capsules be opened and sprinkled on food?

Capsules should be administered according to the approved product labeling. A generic company should not assume that capsule opening or sprinkling is interchangeable with the approved oral-pellet product without supporting compatibility, stability, dose-uniformity, and regulatory data.[1]

Is a liquid Rozlytrek formulation commercially attractive?

Yes. A liquid or reconstitutable suspension could address infants and patients unable to use capsules or pellets. Its development burden would be higher because of chemical stability, microbial control, packaging, and possible 505(b)(2) requirements.

Does a lactose-free Rozlytrek generic have a competitive advantage?

Potentially. Lactose-free and gelatin-free positioning may improve institutional and patient acceptance, but the advantage must justify formulation development, bioequivalence work, and manufacturing cost.

Can a generic company use a different lubricant from magnesium stearate?

Yes, subject to formulation performance and regulatory requirements. Alternative lubricants can support design-around strategies, but changes may affect dissolution, powder flow, capsule filling, and bioequivalence.

What is the highest-value excipient opportunity for Rozlytrek?

Taste-masked, dose-flexible oral pellets are the highest-value opportunity. They address the most important unmet formulation issue: reliable administration of entrectinib to pediatric patients and adults who cannot swallow capsules.

References

1. U.S. Food and Drug Administration. (2024). Rozlytrek (entrectinib) prescribing information. Genentech, Inc.

2. European Medicines Agency. (2024). Rozlytrek: European public assessment report and product information. European Medicines Agency.

3. Roche Products Limited. (2024). Rozlytrek product information. Medicines and Healthcare products Regulatory Agency.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and facilities guidance for industry. FDA.

6. Federal Trade Commission. (2023). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act. FTC.